Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Bevacizumab × NET × Clear all

Phase

Status

Completed 2 Unknown 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 94 Thoracic 49 Gynecologic 27 Breast 24 CNS 22 Genitourinary 10 Head & Neck 6 Other solid neoplasm 4 Dermatologic 4 Tumor-Agnostic 2 Plasma cell 1 Other neoplasm 1 NET 1 Lymphoid 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 4 lanreotide 3 Temozolomide 3 (177)Lu-DOTA-EB-TATE 3 anlotinib 2 Positron Emission Tomography Computed Tomography 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Metformin 2 Everolimus 2 Etoposide 2 Cisplatin 2 Capecitabine 2 Biopsy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 surufatinib 1 sintilimab 1 regorafenib 1 recombinant interferon alpha 2b-like protein 1 pembrolizumab 1 gallium Ga 68 dotatate 1 copper dotatate CU-64 1 cabozantinib 1 amino-acid, glucose, and electrolyte solution 1 Yttrium-90 1 Tomography, Emission-Computed, Single-Photon 1 Thalidomide 1 Tegafur 1 Surgical Procedures, Operative 1 Somatostatin 1 Rose Bengal B 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01203306 2010-09-16

XELBEVOCT

University of Turin, Italy

Phase 2 Unknown

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡